Drug Discovery for Psychiatric Disorders

• Author : Zoran Rankovic,Matilda Bingham,Richard Hargreaves,Eric J. Nestler
• Publisher : Royal Society of Chemistry
• Release : 07 June 2023

This is a wide scope and in-depth coverage of the state of the art and future directions in drug discovery for major psychiatric disorders.

• Author : Matthew Macaluso,Sheldon H. Preskorn,Richard C. Shelton
• Publisher : Springer Nature
• Release : 16 March 2023

The book reviews clinical trial methodology as it pertains to drug development in psychiatry. The reader will understand the process of drug development in psychiatry from discovery through marketing with the help of clinically relevant examples. The reader will appreciate the history of drug development in psychiatry dating back to the era of serendipitous discovery and culminating in an era of new and highly focused targets. Readers will understand how drug development in psychiatry has changed and adapted with the

• Author : Robert A. McArthur,Franco Borsini
• Publisher : Academic Press
• Release : 17 November 2008

Psychiatric Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for psychiatric disorders such as anxiety, obsessive-compulsive disorder, depression, schizophrenia, bipolar disorder, ADHD, and autistic spectrum disorder. Psychiatric Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug

• Author : Tatiana V Lipina,John C Roder
• Publisher : Royal Society of Chemistry
• Release : 28 April 2015

Since the pioneering pharmacotherapy for treatment of schizophrenia in the 1950s by antipsychotics, only a few major innovations have been made, pointing to a general stagnation in the field of pharmacology of schizophrenia. Drug Discovery for Schizophrenia covers new insights in the field of schizophrenia with an aim to advance the understanding of scientists and clinicians in this area and to fuel drug discovery. The book outlines a change in the way schizophrenia is treated by moving away from focusing

• Author : Strategic Research Institute
• Publisher : Unknown
• Release : 07 June 2023

• Author : Rudy Schreiber
• Publisher : Springer Nature
• Release : 17 June 2021

This textbook provides a comprehensive overview of the currently used concepts, approaches and technologies in the discovery and development of new treatments for the full spectrum of disorders of the central nervous system. It guides the reader through all essential steps, from finding an innovative idea, to the registration of a new drug. Divided into four sections, the book starts by presenting a broad perspective on current approaches in central nervous system (CNS) drug discovery. The second section addresses the

• Author : Robert A. McArthur,Franco Borsini
• Publisher : Academic Press
• Release : 24 February 2009

Reward Deficit Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for reward deficit disorders such as alcohol dependence, nicotine dependence, heroin and cocaine addiction, obesity, and gambling and impulse control disorders. Reward Deficit Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic

• Author : Lars F. Gram,Luc P. Balant,Herbert Y. Meltzer,Svein G. Dahl
• Publisher : Springer Science & Business Media
• Release : 07 March 2013

This book contains the papers from invited lecturers as well as selected contributions presented at the 6th International Meeting on Clinical Pharmacology in Psychiatry (I.M.C.P.P.) held in Geneva, Switzerland, 5-7 June 1991. At this meeting the basic theme of the previous meetings in this series (Chicago 1979, Troms0 1980, Odense 1982, Bethesda 1985, Troms0 1988) was continued, namely, to bridge the gap between experimental development and clinical reality in psychopharmacology. After more than 25 years of intensive research in biological psychiatry, basic understanding

• Author : Amir Kalali,Sheldon Preskorn,Joseph Kwentus,Stephen M. Stahl
• Publisher : Cambridge University Press
• Release : 07 June 2012

Central Nervous System disorders have an enormous impact on individuals and on society as a whole. The development of better treatments is crucial and is a major focus of pharmaceutical and biotechnology companies. This book explains the complicated process of CNS drug development in a way that is engaging for any interested professional or student. Chapters cover each stage of drug development, from pre-clinical research through all phases of clinical trials, to reporting to the regulatory authorities. Other key issues

• Author : Jeffrey S. Albert
• Publisher : John Wiley & Sons
• Release : 06 June 2012

New and emerging directions in pharmaceutical research to better treat schizophrenia Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread

• Author : Trevor W. Robbins,Barbara J. Sahakian
• Publisher : Springer
• Release : 22 September 2016

This book covers wide areas of animal and human psychopharmacology with clinical utility in the treatment of psychiatric and neurological (e.g Alzheimer's disease) disorders. The main theme is to develop a new paradigm for drug discovery that questions the claim that animal models or assays fail adequately to predict Phase 3 clinical trials. A new paradigm is advocated that stresses the importance of intermediate staging points between these extremes that depend on suitable translation of findings from animal studies to

• Author : Sanjay J. Mathew,Carlos A. Zarate, Jr.
• Publisher : Springer
• Release : 25 November 2016

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant

• Author : Brian S. Fulton
• Publisher : John Wiley & Sons
• Release : 29 September 2014

With addiction a key target for drug discovery efforts, this book fills an important and timely need for medicinal chemists who need to understand complex neuroscience issues. The author illustrates medicinal chemistry's prominent role in treating addiction and covers specific drugs of abuse including narcotics, stimulants, depressants, nicotine, and marijuana. • Interprets complex neuro- biological and pharmacological information, like the drug-reward system, for medicinal chemists • Emphasizes neurotransmitters and neurochemical mechanisms of addictive drugs • Pulls together information on the many potential drug

• Author : Anonim
• Publisher : Academic Press
• Release : 28 August 2014

This well-established international series examines major areas of basic and clinical research within neuroscience, as well as emerging and promising subfields. This volume concentrates on adenosine receptor science, providing insights useful for actual drug discovery/development in neurology and psychiatry areas. Expertise of contributors Subject including practical drug development from basic science, as translational research taste Structure of contents focusing on two CNS areas for diseases (neurology and psychiatry)

• Author : Joel Dudley,Laura Berliocchi
• Publisher : CRC Press
• Release : 14 July 2017

Nervous system diseases represent a major health concern worldwide. Although important financial and professional investment, their etiology and pathophysiology still remain mostly elusive. Moreover, the clinical need of disease-modifying therapies is still unmet. In the last decades, traditional R&D has failed in identifying new effective therapies in many medical areas and drug repositioning has recently emerged as a promising alternative strategy to de novo drug discovery to improve and accelerate therapeutic development. For the first time, Drug Repositioning: Approaches